BioAge Labs, Inc. (NASDAQ:BIOA) Stock Has Average Price Target of $36.57

BioAge Labs, Inc. (NASDAQ:BIOA) has been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $36.57.

BIOA has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Roth Capital reissued a “buy” rating and issued a $25.00 price objective on shares of BioAge Labs in a research note on Wednesday, September 9th. Wall Street Zen upgraded shares of BioAge Labs from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 13th. Finally, Needham & Company LLC lowered their target price on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st.

BioAge Labs Stock Performance

NASDAQ BIOA opened at $6.36 on Thursday. The company has a market capitalization of $291.92 million, a PE ratio of -2.67 and a beta of 1.08. The business’s fifty day moving average is $10.02 and its 200 day moving average is $15.91. BioAge Labs has a fifty-two week low of $5.04 and a fifty-two week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The firm had revenue of $2.45 million for the quarter. On average, sell-side analysts forecast that BioAge Labs will post -2.45 EPS for the current year.

Institutional Trading of BioAge Labs

Several institutional investors have recently made changes to their positions in BIOA. Engineers Gate Manager LP bought a new stake in shares of BioAge Labs during the second quarter valued at approximately $344,000. Squarepoint Ops LLC lifted its holdings in shares of BioAge Labs by 23.3% in the second quarter. Squarepoint Ops LLC now owns 68,436 shares of the company’s stock worth $1,677,000 after buying an additional 12,916 shares in the last quarter. Corient Private Wealth LP boosted its position in shares of BioAge Labs by 76.7% during the second quarter. Corient Private Wealth LP now owns 40,258 shares of the company’s stock worth $987,000 after acquiring an additional 17,476 shares during the last quarter. Yiheng Capital Management L.P. bought a new position in shares of BioAge Labs during the second quarter worth $4,180,000. Finally, Wellington Management Group LLP grew its stake in BioAge Labs by 39.9% during the second quarter. Wellington Management Group LLP now owns 94,656 shares of the company’s stock valued at $2,320,000 after acquiring an additional 26,975 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.